You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

recurrent nasopharyngeal cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8 Trial

Not yet recruiting
  • Metastatic Nasopharyngeal Carcinoma
  • +2 more
  • Nivolumab
  • +5 more
  • (no location specified)
Aug 21, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (BL-B01D1, capecitabine, gemcitabine)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 31, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (Camrelizumab, Gemcitabine, Cisplatin)

Recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
May 3, 2023

Nasopharyngeal Carcinoma, De-escaltion Therapy Trial in Guangzhou (Reduced-target resection, Full-target resection, Adjuvant

Recruiting
  • Nasopharyngeal Carcinoma
  • De-escaltion Therapy
  • Reduced-target resection
  • +2 more
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
May 25, 2023

Nasopharyngeal Carcinoma, Recurrent Cancer Trial in Guangzhou (Tranilast)

Recruiting
  • Nasopharyngeal Carcinoma
  • Recurrent Cancer
  • Guangzhou, Guangdong, China
    Southern medical university
Nov 15, 2022

Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8 Trial

Not yet recruiting
  • Metastatic Nasopharyngeal Carcinoma
  • +2 more
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Jun 13, 2023

Nasopharyngeal Carcinoma Trial in Brescia (Pembrolizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Brescia, Italy
    Asst Degli Spedali Civili Di Brescia
Mar 29, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (QL1706, Carrelizumab, Gemcitabine)

Recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangzhou, China
    Sun Yat-sen University Cancer Center
Oct 21, 2022

Head and Neck Squamous Cell Carcinoma Trial in Shanghai (BL-B01D1, SI-B003)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 17, 2023

Nasopharyngeal Carcinoma, Leucogen, Chemo Trial in Guangzhou (5-fu, Lobaplatin, Placebo)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • +3 more
  • Guangzhou, Guangdong, China
    Department of Radiation Oncology, Sun Yat-Sen University Cancer
Mar 10, 2023

Nasopharyngeal Carcinoma Trial in China (TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride

Recruiting
  • Nasopharyngeal Carcinoma
  • TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection
  • +2 more
  • Guangzhou, Guangdong, China
  • +3 more
Nov 28, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (Gemcitabine combined with Aptinib and Toripalimab)

Active, not recruiting
  • Nasopharyngeal Carcinoma
  • Gemcitabine combined with Aptinib and Toripalimab
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Apr 24, 2022

Nasopharyngeal Carcinoma Trial in China (Toripalimab, Chemotherapy, Intensity modulated radiotherapy)

Recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
  • +11 more
Aug 30, 2022

Nasopharyngeal Carcinoma, Nasopharyngeal Cancer Trial in Shanghai (Fluzoparib and Camrelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Nasopharyngeal Cancer
  • Fluzoparib and Camrelizumab
  • Shanghai, Shanghai, China
    Fudan Universtiy Shanghai Cancer Centre
Jun 4, 2022

Nasopharyngeal Carcinoma, Recurrent or Metastatic Nasopharyngeal Carcinoma Trial in Guangzhou (Toripalimab and Anlotinib)

Recruiting
  • Nasopharyngeal Carcinoma
  • Recurrent or Metastatic Nasopharyngeal Carcinoma
  • Toripalimab and Anlotinib
  • Guangzhou, China
    Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
Mar 23, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (SHR-1210)

Completed
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Center of Sun-Yat Sen University (CCSYSU)
Apr 1, 2022

Nasopharyngeal Carcinoma, Recurrent or Metastatic Trial in Beijing (KL-A167, Gemcitabine, Cisplatin)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Recurrent or Metastatic
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Mar 23, 2022

Nasopharyngeal Carcinoma by AJCC V8 Stage Trial in Guanzhou (HLX07, HLX10, )

Not yet recruiting
  • Nasopharyngeal Carcinoma by AJCC V8 Stage
  • Guanzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 23, 2022

Recurrent or Metastatic NPC Trial in Hong Kong (Axitinib, Avelumab)

Recruiting
  • Recurrent or Metastatic NPC
  • Hong Kong, Hong Kong
    Department of Clinical Oncology, Prince of Wales Hospital, The C
Jul 18, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (SHR-1701, Gemcitabine, Cisplatin)

Active, not recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Hospital of Guangzhou Sun Yat-sen University
Dec 19, 2021

Nasopharyngeal Carcinoma Trial (procedure, drug, biological)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Biospecimen Collection
  • +9 more
  • (no location specified)
Sep 12, 2023

Granulocyte Colony-Stimulating Factor, PD-1 Inhibitor Trial in Guangzhou (PEG-rhG-CSF)

Recruiting
  • Granulocyte Colony-Stimulating Factor
  • PD-1 Inhibitor
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2022

NPC Trial in Guangzhou (Sintilimab, IBI310)

Active, not recruiting
  • NPC
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 3, 2022

Recurrent Nasopharyngeal Carcinoma Trial in Fuzhou, Nanchang, Shanghai (endonasal endoscopic surgery, radiation therapy(IMRT))

Not yet recruiting
  • Recurrent Nasopharyngeal Carcinoma
  • endonasal endoscopic surgery
  • radiation therapy(IMRT)
  • Fuzhou, Fujian, China
  • +2 more
Feb 20, 2021

Nasopharyngeal Carcinoma, Toripalimab, Recurrent Nasopharyngeal Squamous Cell Carcinoma Trial in Nanning (Toripalimab)

Recruiting
  • Nasopharyngeal Carcinoma
  • +2 more
  • Nanning, Guangxi, China
    Guangxi Medical University Cancer Hospital
Aug 16, 2021